Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RETaliation-Tackling Rare Resistance Alterations to Osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2023

Krebs Matthew G, Popat Sanjay

Abstract excerpt

RET fusions occur as a rare mechanism of acquired resistance to osimertinib in patients with EGFR mutation-positive non-small cell lung cancer. Inhibiting RET alongside osimertinib shows promising clinical activity, but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings. See related article by Rotow et al., p. 2979.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins c-ret

Source

Identifiers

PMID: 37314773
DOI: 10.1158/1078-0432.CCR-23-0993

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RETaliation-Tackling Rare Resistance Alterations to Osimertinib.PMID 37314773Read ↗

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsSemantic proximity Read ↗

Mechanisms of osimertinib resistance and emerging treatment options.Semantic proximity Read ↗

Mechanisms of resistance to RET-directed therapiesSemantic proximity Read ↗

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Semantic proximity Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.Semantic proximity Read ↗

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.Semantic proximity Read ↗

An early look at selective RET inhibitor resistance: new challenges and opportunities.Semantic proximity Read ↗

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the LiteratureSemantic proximity Read ↗

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Semantic proximity Read ↗

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.